A rare-disease drug candidate cleared its pivotal test on September 8, when Pharvaris announced that its oral prophylaxis for hereditary angioedema reduced monthly attack rates by 83 percent compared with placebo in the Phase III CHAPTER-3 study.
Hereditary angioedema is a genetic condition in which uncontrolled bradykinin signaling produces sudden, painful swelling attacks, most dangerously in the airway, where an attack can obstruct breathing. Patients can take medicines on demand when an attack begins, or prophylactic therapies to prevent attacks from starting. The prophylactic options available today are largely injected or infused, and they do not cover every form of the disease. CHAPTER-3 was designed to test whether a once-daily pill could change both of those facts.
The numbers, by subgroup
The trial's headline figure is the 83 percent reduction in mean monthly attack rate versus placebo, which cleared the primary endpoint with high statistical significance. Among the 80 participants with HAE type 1 or type 2, the reduction reached 87 percent. The study also enrolled patients with HAE with normal C1 inhibitor, a form of the disease that has no dedicated oral prophylactic option, making CHAPTER-3 the first pivotal prophylaxis study to evaluate an investigational therapy across all three types.
The design was global, randomized, double-blind, and placebo-controlled: 85 adolescents and adults across 21 countries, randomized two to one to receive 40 milligrams of deucrictibant extended-release once daily or placebo for 24 weeks. All secondary efficacy endpoints were met under a sequential testing procedure. Protection appeared early, with attack reductions starting within the first week and sustained through the full treatment period. Pharvaris also reported reductions from baseline in attack rates and a higher proportion of participants who remained attack-free.
Safety was unremarkable in the way trials prefer: most treatment-emergent adverse events were mild or moderate, there were no treatment-related serious adverse events, and one participant in each group discontinued due to an adverse event. The most common side effects were upper respiratory tract infection, nasopharyngitis, and headache.
Why an oral option changes the arithmetic
Deucrictibant is a small molecule that blocks the bradykinin B2 receptor, the final common pathway of the swelling attacks. It is being developed in two forms: an immediate-release capsule for on-demand treatment of attacks that have already begun, and the extended-release tablet tested in CHAPTER-3 for prevention. The on-demand version is already under FDA review with a decision expected in April, according to the company's disclosures.
The significance of an oral prophylaxis is practical before it is medical. Injectable preventives work, but they impose a needle-based routine on patients for whom attacks are intermittent and unpredictable. A pill removes a substantial treatment burden, which in chronic disease often translates into treatment that actually gets used. The extended-release form is designed for once-daily dosing, and the early onset data addresses a specific worry: injectable therapies sometimes take weeks to reach full effect, while the CHAPTER-3 data show reductions within the first week.
The normal C1 inhibitor subgroup matters commercially and clinically. That form of the disease is less common, harder to diagnose, and has been left out of most pivotal programs because its biology differs from the classic types. A positive result that spans all three forms gives regulators a cleaner file and gives the least-served patients a studied option.
The path to market
Pharvaris plans to submit the U.S. application for the prophylactic indication in the first half of 2027, using CHAPTER-3 as the basis, and to follow in other regions. The open-label CHAPTER-4 extension study continues to collect longer-term data. Topline results from a separate pivotal study in acquired angioedema due to C1 inhibitor deficiency are expected in the first quarter of 2027.
The competitive context is honest: the HAE prophylaxis market is not empty, and an approval would place deucrictibant alongside established injectable therapies rather than in a field of its own. What the pill would offer is not a first mechanism but a first oral convenience, and in a chronic condition that patients manage for decades, convenience is its own efficacy measure.
For patients, the appropriate reading of the announcement is measured optimism: a pivotal trial succeeded, the safety profile looks clean, and the regulatory filing is roughly a year away. The full dataset, with subgroup detail and quality-of-life measures, will arrive at medical congresses before then.
Primary sources
- Pharvaris investor release on CHAPTER-3 topline results.
- Nasdaq and HCPLive for the endpoint detail and subgroup figures.
- The CHAPTER-3 trial record and design as reported in the coverage above.